IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?
This article was originally published in Start Up
Executive Summary
Valuation Watch: an analysis of pre-money step ups for the 2003-04 biotech IPO window demonstrates that public investors are favoring companies in some therapeutic areas over companies in other areas. CNS and jump-start technologies, for example, are doing well.